Lung-Kidney Axis in Cystic Fibrosis: Early Urinary Markers of Kidney Injury Correlate

with Neutrophil Activation and Worse Lung Function

Authors: Grace M. Rosner[#, a], Himanshu B. Goswami[#, a], Katherine Sessions[b], Lindsay K.

Mendyka[b], Brenna Kerin[b], Irma Vlasac[c], Diane Mellinger[b], Lorraine Gwilt[b], Thomas H.

Hampton[a], Martha Graber[b], Alix Ashare[a,b], William T. Harris[d], Brock Christensen[c], Bruce A.

Stanton[a], Agnieszka Swiatecka-Urban[e], Sladjana Skopelja-Gardner[a,c,*]

Affiliations:

a. Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth,

Lebanon, NH, USA.

b. Department of Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.

c. Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH, USA.

d.   AL, USA

e. Department of Pediatrics, University of Virginia, VA, USA

*Corresponding author:
Sladjana Skopelja-Gardner, PhD
Department of Medicine
Dartmouth Hitchcock Medical Center
Department of Immunology and Microbiology
Geisel School of Medicine at Dartmouth
One Medical Center Drive, Lebanon NH 03756.
sladjana.skopelja-gardner@dartmouth.edu

 # co-first authors

Abstract

Background: Adult people with cystic fibrosis (PwCF) have a higher risk of end-stage kidney

disease than the general population. The nature and mechanism of kidney disease in CF are

unknown. This study quantifies urinary kidney injury markers and examines the hypothesis that

neutrophil activation and lung infection are associated with early kidney injury in CF.

Methods: Urinary total protein, albumin, and markers of kidney injury and neutrophil activation,

normalized to creatinine, as well as urinary immune cells, were quantified in CF (n = 48) and

healthy (n = 33) cohorts. Infection burden and chronicity were defined by sputum culture and

serum titers of anti-bacterial antibodies.

Results: PwCF had increased urinary protein levels, consisting of low-molecular-weight tubular

injury markers, independent of glomerular filtration rate (eGFR). This finding suggests

subclinical renal injury processes. Urinary analysis of the CF cohort identified different

associations of urinary injury markers with aminoglycoside exposure, lung function, and

neutrophil activation. High urinary KIM-1 levels and increased prevalence of neutrophils among

urine immune cells correlated with decreased lung function in PwCF. The relationship between

tubular injury and decreased lung function was most prominent in patients harboring chronic

Pseudomonas aeruginosa infection.

Conclusions: Increased urinary tubular injury markers in PwCF suggest early subclinical renal

injury not readily detected by eGFR. The strong association of high urinary KIM-1 and

neutrophils with diminished lung function and high *Pseudomonas aeruginosa* burden suggests

that pulmonary disease may contribute to renal injury in CF.

Introduction

Even though lung disease is the primary cause of morbidity and mortality in CF, extrapulmonary manifestations in the pancreas, intestine, or kidney may contribute to disease outcomes. Advancements in early diagnosis, antibiotic treatment, and most notably, high-efficiency CFTR modulator treatments (HEMT) have remarkably extended the lifespan of people with CF (PwCF). This increased longevity has brought to light a rise in long-term complications, such as chronic kidney disease (CKD), which affects 1 in 7 adults in the United States. The literature estimates that up to 29% of PwCF suffer from CKD [1–3]. The risk of CKD doubles every 10 years of follow-up in PwCF, and PwCF with CKD have a higher risk of developing end-stage renal disease (ESRD) compared to non-CF patients with CKD [2,4]. Despite these alarming figures, the nature of early renal injury and the mechanisms by which inflammatory events in the lung may contribute to kidney pathogenesis in CF remain unknown.

The two most studied contributors to kidney disease in CF are aminoglycosides, used to treat pulmonary exacerbations triggered by *Pseudomonas aeruginosa* (*P. aeruginosa*) infections, and CF-related diabetes (CFRD) [2,5]. Although diabetes is a significant risk of CKD in both non-CF and CF populations [2], it is a less frequent cause of ESRD in CF (24% in CF populations vs. 42% in non-CF populations, p<0.001) [4]. Aminoglycosides disrupt tubular reabsorption, leading to tubular necrosis and acute kidney injury (AKI) [6], though several studies showed that kidney function in PwCF may be independent of prolonged aminoglycoside use [2,7,8]. How infection and lung inflammation may contribute to CKD in PwCF has not been extensively studied. That inflammatory events in the lung can cause kidney injury was first recognized in acute respiratory disease syndrome (ARDS)-mediated AKI, but likely extends to other lung illnesses [9]. In chronic obstructive pulmonary disease (COPD), ~24% of patients had persistent albuminuria, compared to 4% of control subjects, and lower estimated glomerular filtration rate (eGFR) in COPD patients correlated with decreased lung function [10]. In *in vivo* murine studies, intratracheal instillation of lipopolysaccharide (LPS) caused acute renal injury accompanied by both pulmonary and renal inflammation [11]. Whether infection-triggered inflammation or diminished lung function in CF contribute to early kidney injury is unknown. Given the high neutrophil infiltration in the CF lung before and during infection [12–14], and the reported ability of neutrophils

to mediate both local and distal tissue damage [15,16], we hypothesized that activated neutrophils

contribute to kidney injury in PwCF.

Several studies have reported increased levels of a limited number of urinary kidney

injury markers in PwCF [3,17–19], suggesting that kidney damage may develop before it is detected

by standard clinical tests, e.g. albuminuria or eGFR. Neither a decrease in eGFR, which may

occur as late as after $\geq$50% of kidney function loss, nor an increase in albuminuria, a marker of

glomerular dysfunction, provide an insight into disease etiology or capture early signs of renal

tubular injury. This study aims to define early urinary markers of kidney damage and asks if lung

infection and neutrophil-mediated inflammation may play a role in subclinical renal injury in CF.

Methods

Study Cohorts: Urine and blood were collected by written informed consent from a cohort of 48

adult (> 18 years old, Cohort 1) PwCF, recruited between the years 2017 and 2022, at

Dartmouth-Hitchcock Medical Center (DHMC), Lebanon, New Hampshire, through the Clinical

and Translational Research Core (CTRC) of the Dartmouth CF P30. Frozen urine and serum

samples and demographic and clinical data were obtained from the CTRC. Sputum cultures,

patient lung function, and other laboratory measurements were assayed by clinical laboratories at

DHMC. eGFR was computed using the CKD-EPI Creatinine Equation. Urine from 33 healthy

controls (HC) was collected by written informed consent. Cohort characteristics are described in

Supplemental Tables 1 and 2. An additional CF cohort of 11 patients (Cohort 2: 2022-2023,

characteristics in Supplemental Table 3) was recruited to obtain urinary cell pellets for

methylation studies.

Urine collection and processing: Urine samples were processed immediately after collection

and tested for urinary tract infections using Chemstrip[®] Test Strips (Roche). Samples used for

urinary analysis of kidney injury and neutrophil activation were aliquoted and immediately

frozen at -80°C. For urine DNA methylation studies, urine samples were centrifuged ($200g$) to

separate cell-free urine from the cell pellet. Pellets were preserved at -80°C.

Quantification of urinary renal injury markers and neutrophil activation: Total urine

protein levels were quantified with Bradford assay (Pierce™). Urinary albumin and creatinine

levels were determined using the Albuwell Hu and Creatinine Companion ELISA kit (Ethos

Biosciences). Levels of urinary kidney injury proteins were quantified by ELISA: VCAM-1

(R&D); podocalyxin (Invitrogen); beta-NAG (Abcam); or Human Kidney Biomarker Panels

Luminex® (R&D): Panel 1: KIM-1, Cystatin-C, NGAL; Panel 2: β2MG, EGF, TFF-3,

Osteopontin. S100A8/A9 was measured by ELISA (R&D). NETs were quantified by ELISA

measuring MPO: DNA complexes [20]. All protein concentrations were normalized to urinary

creatinine.

Anti-*P. aeruginosa* and anti-*S. aureus* immunoglobulin G (IgG) quantification: Serum

concentrations of anti-*P. aeruginosa* and anti-*Staphylococcus aureus (S. aureus)* IgG were

quantified by ELISA using bacterial lysates generated from overnight cultures of *P. aeruginosa*

PA14 and *S. aureus* USA100 strains [21].

DNA methylation (DNAm)-based deconvolution of cell types in urine. DNA from urine cell

pellets was extracted using Zymogen Mini/Micro Prep Kit and 250 ng bisulfide converted and

run on the EPIC Illumina DNAm array (Dartmouth Genomics Core). Infinium Methylation EPIC

BeadChip v1.0 (EPIC) raw intensity data (IDAT) files were preprocessed using minfi and

Enmix. Probes with out-of-band hybridization >0.05 were excluded, followed by normalization

and background correction using *FunNorm, (*minfi). Probe type correction for EPIC was

completed using BMIQ. EpiDISH 2.12/HEpiDISH was used to calculate cell type proportions [22].

We used an immune-specific reference data set based on the iterative algorithm Identifying

Optimal Libraries (IDOL) [22]. Robust partial correlation methods were used. In Supplemental

Figure 1, we demonstrate that neutrophils cluster together based on the DNAm signature

regardless of the biospecimen (blood or urine).

Statistical analysis: All analyses were performed using GraphPad Prism software and R version

2023.06.0+421. Differences between two means were analyzed using Student's t-test with a

statistical significance of p<0.05. Shapiro-Wilk test was performed to determine the normality of

the data. Differences between the two means were analyzed using Student's t-test for normally

distributed data or a non-parametric t-test for not normally distributed data, with a statistical

significance of p<0.05. Correlations were assessed using Pearson's (normally distributed data) or

non-parametric Spearman's analysis (ranked or not-normally distributed data) or Linear

Regression analysis to control for potential confounders. Robust Principal component analysis [23],

to account for not normally distributed data, was performed using urine proteomic values as well

as clinical factors.

Results

Proteinuria and urinary tubular injury markers are elevated in PwCF.

Adult PwCF (n=48) and healthy controls (HC; n=33) were recruited for this study

(**Supplemental Tables 1-2**). Total urinary protein, normalized to creatinine, was significantly

higher in 29.2% (N = 14) of PwCF, compared to HC (**Fig. 1A, Table 1**). Urinary protein did not

correlate with eGFR (**Fig. 1A**). The increased urinary protein in PwCF was not due to

albuminuria, as the urine albumin/creatinine ratio was comparable between the CF and HC

cohorts (**Fig. 1B**).

To test if elevated urinary protein levels indicate subclinical tubular injury and to identify

early biomarkers of such processes, we used Luminex renal injury panels and ELISA assays to

quantify urinary levels of low-molecular-weight kidney injury markers. As summarized in **Table**

1, urinary levels of tubular injury markers, normalized to urine creatinine, including β2MG,

Cystatin C, KIM-1, TFF3, and β-NAG, were significantly higher in PwCF compared to HC (**Fig.**

1C). Using the HC to define the baseline urinary levels of each biomarker (mean of HC +/- 2

S.D.), we found that 17–48.9% of CF samples had high urinary levels of one or more kidney

injury markers (**Table 1**). Consistent with signs of tubular injury, there was a trend in reduced

urinary epidermal growth factor (uEGF) in PwCF (**Table 1**), which positively correlated with

eGFR (**Fig. 1D**). Levels of other tubular injury markers did not correlate with eGFR, further

supporting that eGFR fails to reflect early signs of tubular damage.

Principal component analysis (PCA) based on urinary measurements of the 10 kidney

injury markers demonstrated 33.3% (n=16/48) of PwCF grouped separately from HC (**Fig. 1E)**

into two populations (encircled). Correlation analyses showed that most tubular injury markers

positively correlated with total urinary protein levels (**Fig. 1F** and **Table 1**) and some

correlations between the urinary injury markers were noted: i) β2MG, Cystatin C, VCAM-1, and

β-NAG and ii) EGF, PDX, and Cystatin C (**Fig. 1F**). PCA did not reveal distinct clustering of

individuals based on the urinary protein concentrations of the kidney injury markers in relation to

eGFR (**Fig. 1G**). Moreover, when patients with eGFR < 90, who may already have signs of a declining kidney function, were excluded from analysis, urinary KIM-1, Cystatin C, TFF3, and β-NAG were still significantly higher in the CF compared to the HC cohort (Supplemental Figure 2). These findings suggest a heterogeneity in the urinary profile of PwCF that is not directly correlated with the clinical measure of kidney function, eGFR.

We considered the potential role of CFRD as it is one of the leading causes of CKD in the general population. Despite its high prevalence in PwCF (37.5%, Supplemental Table 1), CFRD diagnosis was not associated with increased total urine protein/creatinine ratio, though a trend in higher proteinuria in CFRD+ patients was noted (Supplemental Table 4 and **Fig. 1G**). PCA of the urinary levels of kidney injury markers did not reveal a distinct separation of individuals based on their CFRD status (**Fig. 1H**). When using serum hemoglobin A1C (HbA1C) levels to stratify PwCF into non-diabetic (< 5.7), pre-diabetic (5.7–6.5), and diabetic (>6.5) groups, we detected significantly increased uVCAM-1 in the diabetic group, but no association was found with total urine protein, eGFR, or other urinary kidney markers (**Fig. 1J,** Supplemental Table 4).

Given the nephrotoxic nature of aminoglycosides, we next asked if increased urinary levels of tubular injury markers in PwCF are a consequence of treatment with tobramycin (nephrotoxic aminoglycoside, 25% of PwCF), compared to antibiotics with low nephrotoxic risk: azithromycin (41.6% of PwCF) and aztreonam (4.1% of PwCF). Urinary levels of β2MG, cystatin C, and TFF3 were significantly increased in PwCF receiving tobramycin therapy at the time of urine collection, while only uTFF3 was elevated in PwCF receiving azithromycin (**Fig. 1K** and Supplemental Table 4). Together, these findings demonstrate early signs of renal injury in PwCF that are partially associated with glucose dysregulation or aminoglycoside therapy but also uncover increased levels of renal injury markers that in this patient cohort are not associated with either of these two factors.

Decreased lung function and chronic P. aeruginosa infection are associated with markers of early tubular injury in PwCF.

While lung-kidney crosstalk has been recognized in several conditions of lung inflammation [24], how these organs may communicate in CF patients is unknown. To establish a

link between the lung and the kidney in CF we examined if lung function (%FEV_1) correlates

with urinary levels of kidney injury markers. We found that uKIM-1 levels, normalized to

creatinine, negatively correlated with %FEV_1 (**Fig. 2A**), suggesting an inverse relationship

between lung function and kidney injury in PwCF. Low %FEV_1 was most notable in PwCF with

a high burden of mucoid *P. aeruginosa* by sputum culture (**Fig. 2A,** red and blue circles).

Additionally, PwCF with increased sputum burden of mucoid *P. aeruginosa* had significantly

higher uKIM-1 than those with lower infection burden (**Fig. 2B**). No association was found

between non-mucoid *P. aeruginosa* in sputum and %FEV_1 or uKIM-1 levels (not shown). In

support of a relationship between chronic *P. aeruginosa* infection and renal injury, we found that

anti-*P. aeruginosa* IgG levels in the serum of PwCF positively correlated with uKIM-1 levels

(**Fig. 2C**). In contrast, PwCF who had higher sputum *S. aureus* burden had significantly lower

uKIM-1 compared to PwCF with no or low *S. aureus* burden (**Fig. 2D**), suggesting that chronic

S. aureus infection may not be associated with kidney injury in CF. Indeed, anti-*S. aureus* IgG

levels in the serum were negatively correlated with uKIM-1 levels (**Fig. 2E**). These findings

suggest that chronic lung infections with mucoid *P. aeruginosa* strains may be important

mediators of the lung-kidney axis in CF. In support of this model, patients with mucoid *P.*

aeruginosa, but not *S. aureus,* positive sputum culture also had significantly lower levels of

uEGF (**Fig. 2F**). To uncouple the potential contribution of aminoglycoside therapy to higher

uKIM-1 and lower uEGF in PwCF infected with *P. aeruginosa*, we asked if these differences

were most prominent in patients treated with tobramycin. In our cohort, infections among

patients treated with tobramycin were evenly divided between *P. aeruginosa* and *S. aureus.*

Tobramycin-treated patients did not preferentially demonstrate higher uKIM-1 or lower uEGF

levels (Supplemental Figure 3). Furthermore, linear regression analysis adjusted for CFRD,

aminoglycoside therapy, age, and eGFR demonstrated a significant inverse relationship between

uKIM-1 and %FEV1 that is independent of these potential confounders (Supplemental Table 5).

Urinary neutrophil activation and lung disease exacerbation positively correlate with levels of
renal injury markers

Neutrophils are highly abundant innate immune cells in the infected CF lung [13,25]. In

other models of local tissue injury neutrophils have been shown to disseminate to distal organs,

including our prior findings that neutrophils migrate to the kidney following skin injury[15,26]. To

ask if neutrophil activation is associated with kidney injury in PwCF, we quantified urine levels

of calprotectin (S100A8/9) and neutrophil extracellular traps (NETs), known markers of

neutrophil activation [20]. Urinary calprotectin and/or NETs levels, normalized to creatinine,

positively correlated (blue squares) with several urinary markers of tubular (NGAL, KIM-1,

TFF3, β-NAG) and glomerular (PDX) injury (**Fig. 3A**). Levels of urinary calprotectin were

positively correlated with total urine protein (**Fig. 3B**), further suggesting a link between

neutrophil activation and renal injury. To understand the contribution of pulmonary

exacerbation, which was present in 37.5% of PwCF at the time of urine collection, we performed

PCA of urinary injury markers in relation to the pulmonary exacerbation (PEx) status. The

urinary profile in 12/18 patients with a pulmonary exacerbation resembled that of patients

without an exacerbation but there was a group of 6 patients with a pulmonary exacerbation that

clustered separately (**Fig. 3C**). These 6 patients (encircled) had high levels of uNGAL, a tubular

injury marker that is also secreted by activated neutrophils (**Fig. 3C -D**). Both urinary

calprotectin and NGAL were increased in patients with an active PEx at the time of sample

collection, as was total urine protein (**Fig. 3D**). Together, these observations support the model

by which kidney injury in PwCF may be related to neutrophil activation at the time of lung

exacerbation.

Urinary neutrophil levels are elevated in CF patients with decreased lung function.

While increased urinary calprotectin and NETs implicate neutrophil activation in renal

injury in PwCF (**Fig. 3**), these are indirect measurements of neutrophil presence. Since recent

studies have demonstrated that urine cell profiles closely mimic cellular diversity in the kidney

tissue [27,28], we quantified neutrophil levels in the urine of PwCF by leveraging cell-specific DNA

methylation (DNAm) signatures [29]. As cells commit to different lineages, they inherit

characteristic DNAm signatures in their epigenome (Supplemental Figure 1). Utilizing reference-

based cell-type deconvolution of differentially methylated regions (DMRs), we quantified

immune cells in the urine cell pellets from 11 PwCF (**Fig. 4A**). For these studies, we recruited a

second cohort of PwCF as the samples collected in the initial CF cohort did not include urinary

cell pellets (patient characteristics in Supplemental Table 3). Deconvolution of urinary DNAm

data identified myeloid cells (Myel: monocytes and macrophages), neutrophils (Neu), memory B

cells (Bmem), and regulatory T cells (Treg) as the most prevalent immune populations in the

urine cell pellets of PwCF (**Fig. 4B**). Among innate immune cells, the percentage of neutrophils

within all immune cells was significantly higher than that of myeloid cells (**Fig. 4C**).

Interestingly, the percentage of neutrophils in urine immune cells inversely correlated with

%FEV$_1$ (**Fig. 4D**). No relationship was observed between myeloid cells, Treg, or memory B cells

with %FEV$_1$ (**Fig. 4D**). These findings suggest that increased neutrophil presence in the urine is

associated with worse lung function.

Discussion

In this study, we report that PwCF display signs of renal injury, including increased

levels of total urine protein in ~29% and several urinary tubular injury markers (KIM-1, TFF3,

β2MG, cystatin C, and β-NAG) in 17–48.9% of PwCF, in the absence of albuminuria. Lower

urinary EGF correlated with decreased eGFR, suggestive of declining repair capacity of tubular

epithelial cells, an indicator of progressive kidney injury. The increased urinary levels of most

renal injury markers were independent of eGFR and remained increased in the CF cohort with

normal eGFR (> 90). Though CFRD was not associated with higher urinary levels of any renal

injury markers, there was a trend in higher total urine protein in CF patients with CFRD.

Moreover, increased uVCAM-1 in the diabetic group could be due to endothelial cell

dysfunction resulting from hyperglycemia. Only a subgroup of urinary injury markers (β2MG,

cystatin C, and TFF3) were associated with antibiotic treatment. Together, these findings suggest

that different factors likely play a role in urinary tubular injury and contribute to differential

early urinary injury profiles: treatment, CFRD, kidney-intrinsic abnormalities due to the CFTR

mutation, or potentially the response to disease. Our studies reveal several novel associations that

link lung inflammation to renal injury in CF: i) increased uKIM-1 and neutrophil levels in urine

immune cells inversely correlate with lung function; ii) urinary levels of kidney injury markers

and proteinuria positively correlate with urinary markers of neutrophil activation, and iii) urinary

levels of renal injury markers are elevated (KIM-1) or decreased (EGF) in PwCF with *P.*

aeruginosa infection. Though neither aminoglycoside therapy nor CFRD were independently

associated with increased uKIM-1 or decreased uEGF, future larger studies are required to define

the contribution of CFRD simultaneous with aminoglycoside treatment to renal injury following

a pulmonary exacerbation.

Aminoglycoside treatment has been associated with increases in numerous kidney injury

markers acutely and their frequent administration could have chronic effects on renal injury. In

our cohort, no aminoglycosides were administered intravenously and only three kidney injury

markers (b2M, Cystatin C, and TFF3) were significantly correlated with tobramycin treatment,

though this may be reflective of a small retrospective cohort. Since aminoglycosides are usually

administered to treat lung infections and 38% of our cohort had a pulmonary exacerbation at the

time of sample collection, lung inflammation could be a contributing factor to renal injury.

Interestingly, increased urinary levels of these injury markers in PwCF correlated with higher

levels of urinary calprotectin and NETs, markers of neutrophil activation, suggesting a

relationship between inflammation and renal injury in a subset of PwCF. Neutrophils are known

inflammatory responders and are abundant in the CF airway. In other settings of local injury,

neutrophils have been shown to disseminate to other organs, including the kidney[15]. In our

studies, uCalprotectin was associated with total urine protein levels, suggesting a relationship

between neutrophil activation and renal injury. While it is difficult to ascertain whether the

neutrophils are derived from infected and/or inflamed lungs, we found that %FEV_1 is inversely

correlated with the levels of neutrophils in urine cell pellets. Studies in ARDS and COPD

demonstrate that inflammation in the lung can have both acute and chronic consequences on the

kidney [10,30]. However, if and by which mechanism neutrophils may mediate renal injury CF and

whether subpopulations of PwCF would be more susceptible to neutrophil-mediated injury is

unknown. Our analysis revealed a small population of CF patients with a pulmonary

exacerbation who had high urinary levels of NGAL, a urine activation as well as a tubular injury

marker. That uKIM-1 and uEGF levels were correlated with *P. aeruginosa* but not *S. aureus*

infection may point to different contributions of lung pathogens to renal injury.

Another important contributor to the renal susceptibility to injury in PwCF may be

aberrant CFTR function in the kidney. In addition to the apical surfaces of proximal and distal

tubules, CFTR is also highly expressed in the apical endosomes, where it plays a role in the

endocytic uptake of low-molecular-weight (LMW) proteins [31]. The defect in endocytosis of

LMW proteins by the proximal tubular cells in the CFTR-deficient mice is attributed to

decreased levels of cubilin [31]. Therefore, the accumulation of proteins such as β2MG, TFF3, or

NGAL, in the urine of PwCF may in part be a consequence of intrinsic renal CFTR defects.

Studies of lung epithelial and endothelial cells have demonstrated increased expression of

314 adhesion molecules, neutrophil chemoattractants (IL-8, IL-1b), and inflammatory cytokines in

315 the absence of a functional CFTR [32]. Moreover, high peribronchial neutrophil infiltration in CF

316 infants prior to any infection [33,34], suggests that renal endothelial and epithelial intrinsic defects

317 in the CFTR may also contribute to neutrophil recruitment and activation in the kidney. We were

318 not able to capture any CFTR mutation-specific effects due to the small number of non-Class II

319 PwCF and the small number of patients treated with the triple CFTR modulator in this

320 retrospective analysis. However, even in a CF cohort predominantly treated with the triple CFTR

321 modulator (n = 9/11), we detected a wide range of neutrophil levels in urine, which was strongly

322 linked with lung function (Fig. 4). These data suggest that inflammation and neutrophil

323 infiltration, linked to worsened lung function and pulmonary exacerbation (36% of this cohort

324 had a pulmonary exacerbation), may still be contributing to renal injury even in patients treated

325 with HEMT.

326  The limitations of this study include the relatively small sample size and the cross-sectional

327 design, which limit our ability to establish causality and the contribution of each clinical

328 parameter to the observed trends. The lack of associations between some urinary markers with

329 CFRD or aminoglycoside treatment could be due to the small sample size. Studies of larger

330 cohorts will further delineate the impact of CFRD, treatment due to acute illness, the cumulative

331 impact of prior aminoglycoside therapy on kidney injury in CF, and potential additive effects of

332 aminoglycoside therapy and CFRD. Urine samples in CF cohort 1 and matched healthy controls

333 were directly frozen and thus some of the proteins could be derived from cells in urine. Since

334 leukocytes, besides renal tubular epithelial cells, can also produce KIM-1, and activated

335 neutrophils can make NGAL/Lipocalin-2, future studies will define the cellular origin of these

336 markers via analyses of urinary exosomes. Moreover, future studies with larger cohorts and

337 longitudinal design are necessary to better elucidate the effect of treatment type and duration,

338 lung disease flares, and co-morbidities on the underlying kidney injury in PwCF. While the

339 methylation analysis of urine represents a non-invasive way to ask how immune cells may

340 contribute to renal injury signatures, it is plausible that the same methylation signature could

341 identify neutrophils of different functionalities (e.g. low-density immature, normal-density

342 mature, and MDSCs). Thus, future studies will implement more specific cellular methylation

343 profiles of urinary neutrophil subsets. Due to the size of the cohort, sex as a variable was not

carefully considered and will be integrated into statistical analyses in future studies. Future

studies will investigate the effects of HEMT on renal injury processes.

Acknowledgments

Luminex urine analyses were carried out in DartLab, the Immune Monitoring and Flow
Cytometry Shared Resource at the Norris Cotton Cancer Center at Dartmouth, with NCI Cancer
Center Support Grant 5P30 CA023108-41. DNA methylation array study was carried out in the
Genomics and Molecular Biology Shared Resource (RRID:SCR_021293) at Dartmouth which is
supported by NCI Cancer Center Support Grant 5P30CA023108 and NIH S10 (1S10OD030242)
awards. This work was supported by National Institutes of Health (5 P20GM130454-04),
Dartmouth Cystic Fibrosis Pilot Program (P30DK117469), and Cystic
Fibrosis Foundation (SKOPEL24A0-MPI) to S.S.G. and National Institutes of Health (R01
HL151385 and P30 DK117469), Cystic Fibrosis Foundation (STANTO19R0), and
the Flatley Foundation to B.A.S.

Conflict of Interest Statement

Authors declare no conflict of interest.

References

1. Chen, Q., Shen, Y. & Zheng, J. A review of cystic fibrosis: Basic and clinical aspects. *Animal Models*
and Experimental Medicine vol. 4 220–232 Preprint at https://doi.org/10.1002/ame2.12180
(2021).

2. Quon, B. S., Mayer-Hamblett, N., Aitken, M. L., Smyth, A. R. & Goss, C. H. Risk factors for chronic
kidney disease in adults with cystic fibrosis. *Am J Respir Crit Care Med* **184**, 1147–1152 (2011).

3. Lai, S. *et al.* Renal involvement and metabolic alterations in adults patients affected by cystic
fibrosis. *J Transl Med* **17**, (2019).

4. Stevanovic, M. & Graber, M. Primary Causes of ESRD in the US Cystic Fibrosis Population. *Journal*
of the American Society of Nephrology **33**, (2022).

5. Nazareth, D. & Walshaw, M. A review of renal disease in cystic fibrosis. *Journal of Cystic Fibrosis*
vol. 12 309–317 Preprint at https://doi.org/10.1016/j.jcf.2013.03.005 (2013).

6. Mingeot-Leclercq, M.-P. & Tulkens, P. M. *Aminoglycosides: Nephrotoxicity. ANTIMICROBIAL*
AGENTS AND CHEMOTHERAPY vol. 43 (1999).

7. Steinkamp, G. *et al. Renal Function in Cystic Fibrosis: Proteinuria and Enzymuria before and after*
Tobramycin Therapy.

8. McWilliam, S. J., Antoine, D. J., Jorgensen, A. L., Smyth, R. L. & Pirmohamed, M. Urinary
Biomarkers of Aminoglycoside-Induced Nephrotoxicity in Cystic Fibrosis: Kidney Injury Molecule-
1 and Neutrophil Gelatinase-Associated Lipocalin. *Sci Rep* **8**, (2018).

9. Komaru, Y., Bai, Y. Z., Kreisel, D. & Herrlich, A. Interorgan communication networks in the kidney–
lung axis. *Nat Rev Nephrol* (2023) doi:10.1038/s41581-023-00760-7.

10. Shayo, F. K. & Lutale, J. Albuminuria in patients with chronic obstructive pulmonary disease: A
cross-sectional study in an African patient cohort. *BMC Pulm Med* **18**, (2018).

11. Peng, X. *et al.* Protective effects of sphingosine 1-phosphate in murine endotoxin-induced
inflammatory lung injury. *Am J Respir Crit Care Med* **169**, 1245–1251 (2004).

12. Laucirica, D. R., Garratt, L. W. & Kicic, A. Progress in Model Systems of Cystic Fibrosis Mucosal
Inflammation to Understand Aberrant Neutrophil Activity. *Frontiers in Immunology* vol. 11
Preprint at https://doi.org/10.3389/fimmu.2020.00595 (2020).

13. Downey, D. G., Bell, S. C. & Elborn, J. S. Neutrophils in cystic fibrosis. *Thorax* vol. 64 81–88
Preprint at https://doi.org/10.1136/thx.2007.082388 (2009).

14. Gifford, A. M. & Chalmers, J. D. The role of neutrophils in cystic fibrosis. *Current Opinion in*
Hematology vol. 21 16–22 Preprint at https://doi.org/10.1097/MOH.0000000000000009 (2014).

15. Skopelja-Gardner, S. *et al.* Acute skin exposure to ultraviolet light triggers neutrophil-mediated
kidney inflammation. doi:10.1073/pnas.2019097118/-/DCSupplemental.

16.   Wang, J. Neutrophils in tissue injury and repair. *Cell and Tissue Research* vol. 371 531–539
408   Preprint at https://doi.org/10.1007/s00441-017-2785-7 (2018).

409   17.   Steinkamp, G. *et al. Renal Function in Cystic Fibrosis: Proteinuria and Enzymuria before and after*
410   *Tobramycin Therapy*.

411   18.   Al-Aloul, M. *et al.* Renal impairment in cystic fibrosis patients due to repeated intravenous
412   aminoglycoside use. *Pediatr Pulmonol* **39**, 15–20 (2005).

413   19.   Shahin, W. *et al.* Early renal involvement in children with cystic fibrosis. *European Respiratory*
414   *Journal* **52**, PA4627 (2018).

415   20.   Bach, M. *et al.* A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients
416   With Rheumatoid Arthritis. *Arthritis and Rheumatology* **72**, 47–56 (2020).

417   21.   Skopelja-Gardner, S. *et al.* Autoimmunity to bactericidal/permeability-increasing protein in
418   bronchiectasis exhibits a requirement for Pseudomonas aeruginosa IgG response. *European*
419   *Respiratory Journal* vol. 53 Preprint at https://doi.org/10.1183/13993003.01891-2018 (2019).

420   22.   Zheng, S. C., Breeze, C. E., Beck, S. & Teschendorff, A. E. Identification of differentially methylated
421   cell types in epigenome-wide association studies. *Nat Methods* **15**, 1059–1066 (2018).

422   23.   Hubert, M., Rousseeuw, P. J. & Vanden Branden, K. ROBPCA: A new approach to robust principal
423   component analysis. *Technometrics* **47**, 64–79 (2005).

424   24.   Bollenbecker, S., Czaya, B., Gutierrez, O. M. & Krick, S. Lung-kidney interactions and their role in
425   chronic kidney disease-associated pulmonary diseases. *American Journal of Physiology - Lung*
426   *Cellular and Molecular Physiology* vol. 322 L625–L640 Preprint at
427   https://doi.org/10.1152/AJPLUNG.00152.2021 (2022).

428   25.   Tirouvanziam, R. *et al. Profound Functional and Signaling Changes in Viable Inflammatory*
429   *Neutrophils Homing to Cystic Fibrosis Airways*. www.pnas.org/cgi/content/full/ (2008).

430   26.   Wang, J. *et al.* Visualizing the function and fate of neutrophils in sterile injury and repair. *Science*
431   *(1979)* **358**, 111–116 (2017).

432   27.   Abedini, A. *et al.* Urinary single-cell profiling captures the cellular diversity of the kidney. *Journal*
433   *of the American Society of Nephrology* **32**, 614–627 (2021).

434   28.   Fava, A. *et al.* Urine Proteomics and Renal Single-Cell Transcriptomics Implicate Interleukin-16 in
435   Lupus Nephritis. *Arthritis and Rheumatology* **74**, 829–839 (2022).

436   29.   Salas, L. A. *et al.* Enhanced cell deconvolution of peripheral blood using DNA methylation for
437   high-resolution immune profiling. *Nat Commun* **13**, (2022).

438   30.   Park, B. D. & Faubel, S. Acute Kidney Injury and Acute Respiratory Distress Syndrome. *Critical*
439   *Care Clinics* vol. 37 835–849 Preprint at https://doi.org/10.1016/j.ccc.2021.05.007 (2021).

440   31.   Jouret, F. *et al.* Cystic fibrosis is associated with a defect in apical receptor-mediated endocytosis
441   in mouse and human kidney. *Journal of the American Society of Nephrology* **18**, 707–718 (2007).

442   32.   Cabrini, G. *et al.* Role of Cystic Fibrosis Bronchial Epithelium in Neutrophil Chemotaxis. *Frontiers*
443   *in Immunology* vol. 11 Preprint at https://doi.org/10.3389/fimmu.2020.01438 (2020).

444   33.   Margaroli, C. *et al.* Elastase exocytosis by airway neutrophils is associated with early lung damage
445   in children with cystic fibrosis. *Am J Respir Crit Care Med* **199**, 873–881 (2019).

446   34.   Chandler, J. D. *et al.* Myeloperoxidase oxidation of methionine associates with early cystic fibrosis
447   lung disease. *European Respiratory Journal* **52**, (2018).

Figure 1. Urinary levels of tubular proteins indicate subclinical renal injury in adult PwCF. (A)
Total urine protein levels were measured by Bradford assay and normalized to urine creatinine in healthy
control (HC, n =33) and CF (CF, n= 48) cohorts and stratified by eGFR, computed using the CKD-EPI
Creatinine Equation: blue: <60, green: 60-90, grey: 90-120, pink: >120. Significance was defined by a
non-parametric t-test, **p < 0.01. The dotted line represents a positive cutoff (0.87) based on mean HC
(0.45) $\pm$ 2 S.D. (0.21). **(B)** Urinary levels of albumin (uAlbumin) normalized to creatinine in HC and CF
cohorts. Non-parametric-test defined significance, ns = not significant (p > 0.05). **(C)** Urinary levels of
kidney injury markers in HC (pink) and CF (black) cohorts, normalized to urine creatinine. Significance
was determined by mixed effects analysis multiple comparisons with Bonferroni correction (Luminex
panel 1: Cystatin C, NGAL, KIM-1; Luminex panel 2: b2M, TFF3, EGF); non-parametric t-test (bNAG,
PDX); student's t-test (VCAM1) **(D)** Pearson correlation analysis between urinary levels of epidermal
growth factor (log10 uEGF), normalized to urine creatinine, and eGFR, computed as in A. **(E)** Robust

principal component (PC) analysis of urinary kidney injury markers measured in panel C in HC and CF cohorts. Circles indicate two subpopulations of the CF cohort with differential urinary levels of injury markers. **(F)** Spearman correlation analysis of urinary injury markers and total urine protein, normalized to urine creatinine, in the CF cohort. **(G)** Robust PCA of urinary markers measured in panel C in the CF cohort, as a function of eGFR. **(H)** total urine protein normalized to creatinine, in PwCF with (pink) or without (grey) a diagnosis of CF-related diabetes (CFRD), were compared by non-parametric t-test. **(I)** Robust principal component (PC) analysis of urinary markers measured in C in the CF cohort stratified by diagnosis of CFRD (blue) or no diagnosis of CFRD (grey). **(J)** Total urine protein levels, eGFR, and uVCAM-1 levels in PwCF stratified by HbA1c levels: non-diabetic (< 5.7), pre-diabetic ($5.7 – 6.5$), and diabetic (>6.5); non-parametric t-test (total urine protein) and student's t-test (eGFR, uVCAM1); ns = not-significant, $p > 0.05$; **$p < 0.01$. **(J)** Spearman correlation analysis between urinary kidney injury markers measured in C, % FEV1, eGFR, and status of antibiotic, azithromycin (AZ), tobramycin (Tobi), or aztreonam use at the time of sample collection. The color of the squares indicates a significant positive (blue) or negative (red) correlation, and the r coefficient is shown within each square. β2m = β2-microglobulin, Kim-1 = kidney injury marker 1, EGF = epidermal growth factor, OPN = osteopontin, NGAL = Lipocalin 2, TFF3 = Trefoil factor 3 , PDX = Podocalyxin, βNAG = N-acetyl-β-d-glucosaminidase.

Table 1: Urinary kidney injury markers in the CF vs. HC cohorts

CF N=48	Total urine protein	uβ2M	uCystatin C	uNGAL	uKIM-1	uTFF3	uβ-NAG	uVCAM1	uEGF	uOPN	uPDX
Comparison to HC cohort (N=33)											
	higher	higher	higher	higher	higher	higher	higher	higher	lower	lower	lower
p value	0.04*	0.004**	<0.0001***	>1	0.04*	0.03*	0.03*	0.8	>1	0.026*	0.004**
% CF Cohort High / Low#	29.2	21.3	48.9	17.0	17.0	38.3	38.3	23.4	6.4	10.6	19.1
Non-parametric correlation of biomarkers against total urine protein in the CF cohort (p values)		0.0001***	<0.0001***	0.02*	0.41	0.02*	0.0002***	<0.0001***	0.47	0.56	0.01*

% CF cohort High / Low defined as mean of healthy controls +/- 2 standard deviations
β2m = β2-microglobulin, KIM-1 = kidney injury marker 1, EGF = epidermal growth factor, OPN = osteopontin, NGAL = Lipocalin 2, TFF3 = Trefoil factor 3 , PDX = Podocalyxin, βNAG = N-acetyl-β-d-glucosaminidase; All urine measurements normalized to urine creatinine; linear regression adjusted for CFRD; all significant relationships are positive.

Figure 2. High urinary KIM-1 levels are associated with worse lung function and increased mucoid *P. aeruginosa* **burden in PwCF. (A)** Pearson correlation analysis between urinary KIM-1 (uKIM-1) normalized to urine creatinine and percent predicted forced expiratory volume in 1 second (%FEV1, n =48) in the CF cohort. Distribution of the mucoid *P. aeruginosa* burden (none = black, few = green, moderate = blue, many = red) in sputum culture in relation to %FEV1 and uKIM-1. **(B)** Levels of uKIM-1 in PwCF with no (none), few, and moderate/many mucoid *P. aeruginosa* colonies in the sputum culture were compared by one-way ANOVA with Bonferroni post-hoc (ns = not significant, $p > 0.05$; *$p < 0.05$). **(C)** Non-parametric Spearman correlation analysis between uKIM-1 levels and anti-*P. aeruginosa* IgG serum titres (n = 27 PwCF). **(D)** Levels of uKIM-1 in PwCF with no (none), few, and moderate/many *S. aureus* colonies in the sputum culture were compared by one-way ANOVA with Bonferroni post-hoc (ns = not significant, $p > 0.05$;   *$p < 0.05$). **(E)** Non-parametric Spearman correlation analysis between uKIM-1 levels and anti-*S. aureus* IgG serum titres (n = 27 PwCF). **(F)** Urinary levels of EGF (uEGF), normalized to urine creatinine, in PwCF colonized with *P. aeruginosa* (left) or *S. aureus* (right) by sputum culture were compared to PwCF not colonized with each pathogen by Student's t-test (n=48, ns = not significant, $p > 0.05$; *$p < 0.05$).

Figure 3. High urinary levels of tubular injury markers correlate with urinary calprotectin and NETs, in the context of pulmonary exacerbation. (**A**) Non-parametric Spearman correlation matrix of urinary kidney injury markers measured in Figure 1C, normalized to urine creatinine, with urinary markers of neutrophil activation: neutrophil extracellular traps (NETs, MPO: DNA complexes) and calprotectin (S100A8/A9), normalized to creatinine. The color of the squares indicates a significant positive (blue) or negative (red) correlation, with the r coefficient shown within each square (n = 48). (**B**) Non-parametric Spearman correlation analysis between urinary calprotectin (uCalprotectin) and total urine protein, both normalized to urine creatinine (Cr) (n = 48). (**C**) Robust principal component (PC) analysis of urinary markers measured in C in the CF cohort stratified by the status of the pulmonary exacerbation (PEx): present at the time of urine sample collection (blue) or no PEx at the time of sample collection (grey). (**D**) Urinary levels of calprotectin, NGAL, and total protein, normalized to urine creatinine (Cr), in PwCF segregated by the state of pulmonary exacerbation at the time of urine sample collection. Statistical significance determined by Student's t-test or non-parametric t-test (n=48, *p < 0.05, **p < 0.01).

Figure 4. Urinary neutrophil levels correlate with worse lung function in PwCF. (A) Urine cell pellets and cell-free supernatants were separated by centrifugation. DNA was extracted from frozen cell pellets, and 250ng was run on an Illumina EPIC DNA methylation (DNAm) array for deconvolution of different immune cell populations. **(B)** Deconvolution of DNAm data demonstrated the presence of neutrophils (Neu), myeloid cells (Myel: monocytes and/or macrophages), regulatory T cells (Treg), memory B cells (Bmem), and basophils (Bas) in the urine of PwCF, within all immune cells. **(C)** The percentages of neutrophils and myeloid cells within all immune cells in urine were compared by Student's t-test, n = 11, *p < 0.05. **(D)** Pearson's correlation analyses between the percentage of Neu and Myel cells within urine immune cells (left) or the percentage of Treg and Bmem (right) and percent predicted forced expiratory volume in 1 second (%FEV1, n=11).

576 **Supplemental Material**

578 **Supplemental Table 1: Characteristics of the CF and Healthy Cohorts**

Cohort	N	Mean age	Female (%)	Male (%)
Healthy (HC)	30	31.7 ± 10.3	55.0	45.0
CF	48	32 ± 8.2	43.7	56.2

CF Cohort	N	Percent (%)
Antibiotics	30	62.5
Aminoglycosides	34	70.8
Azithromycin (oral)	20	41.6
Tobramycin (inhaled)	12	25.0
Aztreonam (inhaled)	2	4.1
CFTR Correctors	29	60.4
Ivakaftor/Lumakaftor	9	18.7
Lumakaftor	1	2.0
Ivakaftor	4	8.3
Tezakaftor/Ivakaftor	4	8.3
Trikafta	11	22.9
Lung Transplant	2	4.1
Diabetes	18	37.5
CFRD	14	29.8
Type II	4	8.3
Infection		
Pseudomonas aeruginosa	24	50.0
Staphylococcus aureus	27	56.2
Burkholderia	3	6.2
Aspergillus fumigatus	5	10.4
Candida albicans	9	18.7
CFTR Mutations		
Class II	29	60.4
Class I/II	3	6.2
Class I/III	2	4.1
Class II/III	4	8.3
Class II/IV	9	18.7
Class I/IV	1	2.0

581 **Supplemental Table 2: Clinical parameters of the CF cohort.**

Clinical covariates	Range in CF cohort #1 (Average ± SD)	Normal range
eGFR	106.4 ± 66.34	>= 90 mL/min/1.73m^2
%FEV1	71.8 ± 22.6	>80%
Pulmonary Exacerbation	*37.5%*	
Hb1Ac	6.7 ± 2.1	4–5.6%
Hematocrit	42.5 ± 2.57	Male: 38.3–48.6%
	37.7 ± 3.92	Female: 35.5–44.9%
Serum bicarbonate	25.8 ± 3.54	22–29 mEq/L

Supplemental Table 3: CF Cohort 2 (Figure 4) patient characteristics.

CF Cohort	N	Percent (%)
Antibiotics	5	45.4
Azithromycin	4	36.3
Tobramycin	3	27.2
Aztreonam	4	36.3
CFTR Correctors	9	81.8
Elexacaftor/tezacaftor/ivacaftor	9	81.8
CFRD	7	63.6
Infection	6	54.5
Pseudomonas aeruginosa	3	27.2
Staphylococcus aureus	3	27.2
CFTR Mutations		
Class II	6	54.5
Class II/III	3	27.2
Class II/IV	2	18.1

Clinical covariates	Range in CF cohort #2 (Average ± SD)	Normal range
eGFR	116.63 ± 24.73	>= 90 mL/min/1.73m^2
%FEV1	54 ± 23.34	>80%
Pulmonary Exacerbation	*36.4%*	
Hb1Ac	6.7 ± 2.1	4–5.6%
Hematocrit	44 ± 0.89	Male: 38.3–48.6%
	37.93 ± 7.20	Female: 35.5–44.9%
Serum bicarbonate	25.9 ± 2.64	22–29 mEq/L

Supplemental Table 4: Correlation analysis of urinary kidney injury markers and clinical parameters in PwCF

CF N=48	Total Urine Protein	uβ2M	uCystatin C	uNGAL	uKim-1	uTFF3	uβ-NAG	uVCAM1	uEGF	uOPN	uPDX
eGFR	-	-	-	-	-	-	-	-	0.02*	-	0.001*
%FEV1	-	-	-	-	0.01*	-	-	-	-	-	-
Hypertension	-	-	-	-	-	-	-	0.02*	0.0004***	0.04*	-
Diabetes	-	-	-	-	-	-	-	0.02*	-	-	-
HbA1c	-	-	-	-	-	-	-	0.02*	-	-	-
Hematocrit#	0.007**	-	0.01*	0.002**	-	-	-	-	-	0.01*	0.0005***
Serum Bicarb	-	-	-	-	-	-	-	-	-	-	-
Lung transplant	-	-	-	-	-	-	-	-	-	-	-
BMI	-	-	-	-	-	-	-	-	-	-	-
Age	-	-	-	-	-	-	-	0.03*	0.0005***	-	-
Sex				<0.001***					0.01*		<0.0001*
Azithromycin	-	-	-	-	-	0.03*	-	-	-	-	-
Tobramycin		0.03*	0.005**	-	-	0.0008***	-	-	-	-	-
Aztreonam	-	-	-	-	-	0.04*	-	-	-	-	-
Elexacaftor/ tezacaftor/ ivacaftor	-	-	-	-	-	-	-	-	-	0.01*	-

#All correlations with hematocrit levels are negative
β2m = β2-macroglobulin, Kim-1 = kidney injury marker 1, EGF = epidermal growth factor, OPN = osteopontin, NGAL = Lipocalin, TFF3 = Trefoil factor 3 , PDX = Podocalyxin, βNAG = N-acetyl-β-d-glucosaminidase; BMI = Body Mass Index, HbA1c = Heamoglobin A1c;
All urine measurements normalized to urine creatinine

Supplemental Table 5: Multivariable regression analysis of uKIM-1 and %FEV1 adjusted for CFRD, Aminoglycosides (Tobi), Age, and eGFR

Parameter estimates	Variable	Estimate	Standard error	95% CI (asymptotic)	|t|	P value	P value summary
β0	Intercept	1.190	0.3670	0.4494 to 1.931	3.243	0.0023	**
β1	% FEV1	-0.004947	0.002155	-0.009296 to -0.0005979	2.296	0.0268	*
β2	CFRD[0.0]	-0.05190	0.1004	-0.2545 to 0.1508	0.5168	0.6080	ns
β3	Tobi[1]	0.01490	0.1089	-0.2048 to 0.2346	0.1369	0.8917	ns
β4	Age	-0.001697	0.006249	-0.01431 to 0.01091	0.2715	0.7873	ns
β5	eGFR	-0.0001061	0.001524	-0.003181 to 0.002969	0.06963	0.9448	ns

604 **Supplemental Figures:**

605
606

607 **Supplemental Figure 1:** Unbiassed clustering of blood and urine samples using 50 CpG sites
608 with known neutrophil-specific DNAm status results in grouping by neutrophil proportion, not
609 specimen type.

610
611

613 **Supplemental Figure 2:** Concentration of urinary kidney injury markers in healthy controls
614 (HC, n = 33) and PwCF with eGFR > 90 (CF, n = 35). normalized to urine creatinine. Significance

615   was determined non-parametric t-test for not normally distributed data or Student's t-test for lognormally
616   and normally distributed data: *p<0.05, ****p < 0.0001.

619

620   **Supplemental Figure 3:** Treatment with Tobramycin (green dots) at the time of sample
621   collection is not associated with higher uKIM-1 (A-B) or lower uEGF (C) in patients infected
622   with P. aeruginosa. uKIM-1 = Urinary Kidney Injury Marker 1; uEGF = urinary Epidermal
623   Growth Factor. Statistical significance defined by (A) Pearson's correlation analysis, (B) One-
624   way ANOVA with Bonferroni post-hoc, and (C) Student's t-test. *p < 0.05.